Rutgers: Buprenorphine, Not Methadone, May Be Safer Treatment For Opioid-Use Disorder During Pregnancy
December 01, 2022
December 01, 2022
NEW BRUNSWICK, New Jersey, Dec. 1 (TNSjou) -- Rutgers University issued the following news:
* * *
Different treatments can impact maternal and neonatal health outcomes, according to a Rutgers pharmacoepidemiologist
* * *
People with opioid-use disorder who are pregnant may have more favorable neonatal health outcomes when using buprenorphine, an active ingredient in suboxone and other medications approved for treatment of opioid-use disorder, c . . .
* * *
Different treatments can impact maternal and neonatal health outcomes, according to a Rutgers pharmacoepidemiologist
* * *
People with opioid-use disorder who are pregnant may have more favorable neonatal health outcomes when using buprenorphine, an active ingredient in suboxone and other medications approved for treatment of opioid-use disorder, c . . .